UTRS (Minerva Surgical) Total Receivables: $7.57 Mil (As of Sep. 2023)


What is Minerva Surgical Total Receivables?

Minerva Surgical UTRS -99.00% Total Receivables is $7.57 Mil as of Sep. 2023.

Minerva Surgical's Total Receivables for the quarter that ended in Sep. 2023 was $7.57 Mil.

Minerva Surgical Total Receivables Related Terms

Minerva Surgical Total Receivables Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Total Receivables Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Receivables
3.95 8.38 7.29 7.24

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.79 7.24 7.39 7.95 7.57

Minerva Surgical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $7.57 Mil mean?
Minerva Surgical (UTRS) has a Total Receivables of $7.57 Mil as of Sep. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Minerva Surgical and its competitors.
Is Minerva Surgical's Total Receivables too high?
Minerva Surgical's current Total Receivables is $7.57 Mil.
How does Minerva Surgical's Total Receivables compare to PAVM and ELUT?
Minerva Surgical's Total Receivables of $7.57 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Minerva Surgical and its competitors. Minerva Surgical's current Total Receivables is $7.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current Total Receivables of $7.57 Mil. The current Total Receivables is $7.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current Total Receivables is $7.57 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.